Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 1.558 EUR -0.76% Market Closed
Market Cap: 99.4m EUR
Have any thoughts about
Oryzon Genomics SA?
Write Note

Intrinsic Value

ORY's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ORY stock under the Base Case scenario is 1.446 EUR. Compared to the current market price of 1.558 EUR, Oryzon Genomics SA is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ORY Intrinsic Value
1.446 EUR
Overvaluation 7%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Oryzon Genomics SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ORY cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ORY?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Oryzon Genomics SA

Provide an overview of the primary business activities
of Oryzon Genomics SA.

What unique competitive advantages
does Oryzon Genomics SA hold over its rivals?

What risks and challenges
does Oryzon Genomics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Oryzon Genomics SA.

Provide P/S
for Oryzon Genomics SA.

Provide P/E
for Oryzon Genomics SA.

Provide P/OCF
for Oryzon Genomics SA.

Provide P/FCFE
for Oryzon Genomics SA.

Provide P/B
for Oryzon Genomics SA.

Provide EV/S
for Oryzon Genomics SA.

Provide EV/GP
for Oryzon Genomics SA.

Provide EV/EBITDA
for Oryzon Genomics SA.

Provide EV/EBIT
for Oryzon Genomics SA.

Provide EV/OCF
for Oryzon Genomics SA.

Provide EV/FCFF
for Oryzon Genomics SA.

Provide EV/IC
for Oryzon Genomics SA.

Show me price targets
for Oryzon Genomics SA made by professional analysts.

What are the Revenue projections
for Oryzon Genomics SA?

How accurate were the past Revenue estimates
for Oryzon Genomics SA?

What are the Net Income projections
for Oryzon Genomics SA?

How accurate were the past Net Income estimates
for Oryzon Genomics SA?

What are the EPS projections
for Oryzon Genomics SA?

How accurate were the past EPS estimates
for Oryzon Genomics SA?

What are the EBIT projections
for Oryzon Genomics SA?

How accurate were the past EBIT estimates
for Oryzon Genomics SA?

Compare the revenue forecasts
for Oryzon Genomics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Oryzon Genomics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Oryzon Genomics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Oryzon Genomics SA compared to its peers.

Compare the P/E ratios
of Oryzon Genomics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Oryzon Genomics SA with its peers.

Analyze the financial leverage
of Oryzon Genomics SA compared to its main competitors.

Show all profitability ratios
for Oryzon Genomics SA.

Provide ROE
for Oryzon Genomics SA.

Provide ROA
for Oryzon Genomics SA.

Provide ROIC
for Oryzon Genomics SA.

Provide ROCE
for Oryzon Genomics SA.

Provide Gross Margin
for Oryzon Genomics SA.

Provide Operating Margin
for Oryzon Genomics SA.

Provide Net Margin
for Oryzon Genomics SA.

Provide FCF Margin
for Oryzon Genomics SA.

Show all solvency ratios
for Oryzon Genomics SA.

Provide D/E Ratio
for Oryzon Genomics SA.

Provide D/A Ratio
for Oryzon Genomics SA.

Provide Interest Coverage Ratio
for Oryzon Genomics SA.

Provide Altman Z-Score Ratio
for Oryzon Genomics SA.

Provide Quick Ratio
for Oryzon Genomics SA.

Provide Current Ratio
for Oryzon Genomics SA.

Provide Cash Ratio
for Oryzon Genomics SA.

What is the historical Revenue growth
over the last 5 years for Oryzon Genomics SA?

What is the historical Net Income growth
over the last 5 years for Oryzon Genomics SA?

What is the current Free Cash Flow
of Oryzon Genomics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Oryzon Genomics SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oryzon Genomics SA

Current Assets 13.9m
Cash & Short-Term Investments 10.1m
Receivables 3.8m
Other Current Assets 7.1k
Non-Current Assets 96.8m
Long-Term Investments 25.8k
PP&E 418.6k
Intangibles 94m
Other Non-Current Assets 2.4m
Current Liabilities 14.6m
Accounts Payable 2.4m
Accrued Liabilities 452.7k
Short-Term Debt 4.8m
Other Current Liabilities 7m
Non-Current Liabilities 9.5m
Long-Term Debt 3.2m
Other Non-Current Liabilities 6.3m
Efficiency

Earnings Waterfall
Oryzon Genomics SA

Revenue
0 EUR
Cost of Revenue
-1.1m EUR
Gross Profit
-1.1m EUR
Operating Expenses
-3.4m EUR
Operating Income
-4.5m EUR
Other Expenses
657.6k EUR
Net Income
-3.8m EUR

Free Cash Flow Analysis
Oryzon Genomics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ORY Profitability Score
Profitability Due Diligence

Oryzon Genomics SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Negative Free Cash Flow
Negative ROIC
Negative ROE
Negative Operating Income
36/100
Profitability
Score

Oryzon Genomics SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

ORY Solvency Score
Solvency Due Diligence

Oryzon Genomics SA's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Negative Net Debt
Short-Term Solvency
52/100
Solvency
Score

Oryzon Genomics SA's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ORY Price Targets Summary
Oryzon Genomics SA

Wall Street analysts forecast ORY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ORY is 6.222 EUR with a low forecast of 2.323 EUR and a high forecast of 12.6 EUR.

Lowest
Price Target
2.323 EUR
49% Upside
Average
Price Target
6.222 EUR
299% Upside
Highest
Price Target
12.6 EUR
709% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ORY?

Click here to dive deeper.

Dividends

Oryzon Genomics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for ORY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Oryzon Genomics SA Logo
Oryzon Genomics SA

Country

Spain

Industry

Biotechnology

Market Cap

98.8m EUR

Dividend Yield

0%

Description

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

Contact

BARCELONA
Cornella de Llobregat
Sant Ferran 74
+34935151313.0
www.oryzon.com

IPO

2015-12-10

Employees

44

Officers

Co-Founder, Chairman, CEO & President
Dr. Carlos Manuel Buesa Arjol
Director of Operations, COO & CFO
Mr. Enric Rello Condomines
Chief Scientific Officer
Mr. Jordi Xaus Pey
Head of Internal Audit & Compliance
Mr. Xavier Perpinya Ribera
Chief Business Development Officer
Mr. Emili Torrell Cortada
Chief Intellectual Property Officer
Ms. Neus Virgili Bernado
Show More
Chief Medical Officer of CNS
Dr. Michael Thomas Ropacki Ph.D.
Chief of Clinical Operations
Ms. Sonia Paloma Gutierrez Bezon
Secretary
Mr. Augusto Pinel Rubio
Show Less

See Also

Discover More
What is the Intrinsic Value of one ORY stock?

The intrinsic value of one ORY stock under the Base Case scenario is 1.446 EUR.

Is ORY stock undervalued or overvalued?

Compared to the current market price of 1.558 EUR, Oryzon Genomics SA is Overvalued by 7%.

Back to Top